Thursday 16 October, 2025
Introduction: Salmeterol is a commonly used β2-agonist included on the List of Prohibited Substances and Methods of the World Anti-Doping…
Read moreAbstracts
Pharmacometrics-based analysis of long-acting cabotegravir over 6 months in real-life people living with HIV in Switzerland
Thursday 16 October, 2025
Introduction: The present study is part of an ongoing nationwide multicenter observational study within the Swiss HIV Cohort Study for…
Read morePopulation pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration
Thursday 16 October, 2025
Objectives: Tenofovir alafenamide (TAF) is gradually replacing tenofovir disoproxil fumarate (TDF), both prodrugs of tenofovir (TFV), in HIV prevention and…
Read moreStandards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Thursday 16 October, 2025
Introduction/Objectives: One of the milestones in tuberculosis (TB) drug development is a phase 2a trial, also known as an early…
Read moreTowards model-informed design of antibiotic therapies: understanding the impact of antibiotics on bacterial physiology & growth.
Thursday 16 October, 2025
Introduction and objectives: Antimicrobial resistance is on the rise globally. Increased levels of resistance have been reported across bacterial strains…
Read morePKPDAI: Unlocking Pharmacokinetic Data from Tables with Natural Language Processing
Thursday 16 October, 2025
Introduction: A centralised, standardised Pharmacokinetic (PK) database is a prerequisite for PK parameter predictions to benefit from the full potential of…
Read moreBenefits of integrating machine learning with clinical pharmacology principles for predictive pharmacokinetic modeling
Thursday 16 October, 2025
Introduction: Machine learning (ML) applications in clinical pharmacology have been rapidly increasing over the last several years (1). While most…
Read moreFavipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections
Thursday 16 October, 2025
Introduction Favipiravir is a broad-spectrum antiviral licensed to treat influenza in adults and is currently not licensed in children [1,2]….
Read morePharmacokinetics of cefotaxime in intensive care patients: exploration of the sources of variability with a population model
Thursday 16 October, 2025
Objectives: Cefotaxime is a beta-lactam antibiotics commonly used in intensive care unit (ICU) patients. In this population, pathophysiological modifications induce a…
Read moreBuilding evidence on the PKPD relationship with bispecific co-stimulatory antibodies using in vitro data: FAP-4-1BBL example
Thursday 16 October, 2025
Objectives: FAP-4-1BBL is a bispecific antibody currently in clinical development for solid tumors. FAP-4-1BBL exerts 4-1BB-associated T-cell activation only while…
Read more